On The Pen With Dave Knapp offers a weekly, in-depth analysis of the latest developments in diabetes and obesity therapies, particularly focusing on incretin mimetics like Ozempic, Wegovy, Mounjaro, and Zepbound, as well as emerging investigational treatments. Host Dave Knapp distills complex scientific data and industry news, making it accessible while providing critical insights into clinical trials, drug efficacy, pricing, and their implications for patient care and personalized metabolic health. The podcast targets healthcare professionals, patients managing diabetes or obesity, and anyone interested in the cutting-edge science and market dynamics of metabolic medicine. It stands out for its timely updates, detailed breakdowns of research, and a commitment to informing its community about significant advancements in a rapidly evolving medical field.